When Bazedoxifene is combined with conjugated estrogen, what is its primary purpose?

The primary purpose of combining Bazedoxifene with conjugated estrogen is to prevent endometrial hyperplasia. Bazedoxifene is a selective estrogen receptor modulator (SERM) that acts as an antagonist in the endometrium. This means that while conjugated estrogen can stimulate the endometrium and potentially lead to hyperplasia, Bazedoxifene counters this effect, thereby reducing the risk of abnormal cell growth in the uterine lining.

This combination is particularly important for postmenopausal women who are receiving estrogen therapy, as the addition of Bazedoxifene mitigates the associated risk of endometrial hyperplasia that arises from unopposed estrogen therapy. Consequently, this combination provides a therapeutic approach that allows for the benefits of estrogen, such as alleviating menopausal symptoms, while ensuring uterine health is maintained.

Bazedoxifene's role in enhancing bone density and controlling menopausal symptoms is secondary to its primary function of preventing endometrial hyperplasia.